D.Western Therapeutics Institute, Inc.
  • Business Outline
  • Pipeline
  • IR
  • DWTI’s Approach
  • About DWTI
  • FAQ
  • Glossary
  • 日本語
Business Outline
  • Our business model
  • Core Technology
Pipeline
  • Ripasudil hydrochloride hydrate
  • H-1337
  • DW-1001
  • DW-1002
  • DW-5LBT
  • DWR-2206
IR
  • Management Policy
    • To Shareholders/Investors
    • Issues to be addressed
    • Business Risks
    • Corporate Governance
  • Financial Information
    • Earnings Highlights
    • Financial Position
    • Cash Flow
  • IR Library
  • Five Unique Features of DWTI
    • Business model
    • Successful launch (commercialization)
    • Focus on ophthalmology
    • Growth trajectory
    • Growth Strategies
  • IR News
  • IR Calendar
  • Stock Information
  • Stock Quote
  • IR Policy / Disclaimer
About DWTI
  • Corporate Profile
  • Corporate Philosophy
  • CEO Message
  • Board of Directors
  • History
PAGE TOP
Business Outline
  • Our business model
  • Core Technology
Pipeline
  • Ripasudil hydrochloride hydrate
  • H-1337
  • DW-1001
  • DW-1002
  • DW-5LBT
  • DWR-2206
IR
  • IR News
  • Management Policy
  • Financial Information
  • IR Library
  • Five Unique Features of DWTI
  • IR Calendar
  • Stock Information
  • Stock Quote
  • IR Policy / Disclaimer
  • Contact Us
DWTI’s Approach
About DWTI
  • Corporate Profile
  • Corporate Philosophy
  • CEO Message
  • Board of Directors
  • History
  • About glaucoma
  • Glossary
  • FAQ
  • Site Policy
  • Privacy Policy
Copyright © D.Western Therapeutics Institute, Inc. All Rights Reserved.